Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 18/20 | 0.69 |
| ▸ | PDE1A | P54750 | 2/20 | 0.66 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14243423 | 0.85 | PDE4A (0.85) | PDE4APDE1APDE1B | |
| SCHEMBL29790189 | 0.85 | PDE4A (0.85) | PDE4APDE1APDE1B | |
| SCHEMBL14158310 | 0.85 | PDE4A (0.85) | PDE4APDE1APDE1B | |
| SCHEMBL2362160 | 0.84 | PDE4A (0.61) | PDE4APDE1APDE1B | |
| SCHEMBL2362468 | 0.84 | PDE4A (0.63) | PDE4APDE1APDE1B | |
| SCHEMBL2361671 | 0.83 | PDE4A (0.62) | PDE4APDE1APDE1B | |
| SCHEMBL18928137 | 0.80 | PDE1A (0.87) | PDE4APDE1APDE1B | |
| SCHEMBL2472569 | 0.80 | PDE1A (0.87) | PDE4APDE1APDE1B | |
| SCHEMBL14243419 | 0.80 | PDE1A (1.00) | PDE4APDE1APDE1B | |
| SCHEMBL2509883 | 0.80 | PDE4A (0.79) | PDE4APDE1APDE1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12435093-B2 | Free base crystals | INTRA-CELLULAR THERAPIES, INC. (US) | 2025-10-07 | — | — | US | disclosed |
| US-20230174543-A1 | FREE BASE CRYSTALS | INTRA-CELLULAR THERAPIES, INC. (US) | 2023-06-08 | — | — | US | disclosed |
| US-20230174543-A1 | FREE BASE CRYSTALS | INTRA-CELLULAR THERAPIES, INC. (US) | 2023-06-08 | — | — | US | disclosed |
| WO-2021226407-A1 | FREE BASE CRYSTALS | INTRA-CELLULAR THERAPIES, INC. (US) | 2021-11-11 | — | — | WO | disclosed |
| WO-2021226407-A1 | FREE BASE CRYSTALS | INTRA-CELLULAR THERAPIES, INC. (US) | 2021-11-11 | — | — | WO | disclosed |
| EP-3010509-B1 | FREE BASE CRYSTALS | INTRA CELLULAR THERAPIES INC (US) | 2021-07-28 | — | — | EP | disclosed |
| EP-3010509-B1 | FREE BASE CRYSTALS | INTRA CELLULAR THERAPIES INC (US) | 2021-07-28 | — | — | EP | disclosed |
| EP-3733675-A1 | SALT CRYSTALS OF A PDE1 INHIBITOR | Intra-Cellular Therapies, Inc. (US) | 2020-11-04 | — | — | EP | disclosed |
| EP-3733675-A1 | SALT CRYSTALS OF A PDE1 INHIBITOR | Intra-Cellular Therapies, Inc. (US) | 2020-11-04 | — | — | EP | disclosed |
| EP-3702358-A1 | PROCESS FOR PREPARING SALTS OF A KNOWN PDE1 INHIBITOR | Intra-Cellular Therapies, Inc. (US) | 2020-09-02 | — | — | EP | disclosed |
| US-20160145261-A1 | FREE BASE CRYSTALS | INTRA-CELLULAR THERAPIES, INC. (US) | 2016-05-26 | — | — | US | disclosed |
| US-20160083390-A1 | ORGANIC COMPOUNDS | LI PENG (US) | 2016-03-24 | — | — | US | disclosed |
| US-20150259353-A1 | SALT CRYSTALS | INTRA-CELLULAR THERAPIES, INC. | 2015-09-17 | — | — | US | disclosed |
| US-20150259353-A1 | SALT CRYSTALS | INTRA-CELLULAR THERAPIES, INC. | 2015-09-17 | — | — | US | disclosed |
| US-20150259353-A1 | SALT CRYSTALS | INTRA-CELLULAR THERAPIES, INC. | 2015-09-17 | — | — | US | disclosed |
| US-20150038474-A1 | ORGANIC COMPOUNDS | LI PENG (US) | 2015-02-05 | — | — | US | disclosed |
| WO-2014205354-A2 | FREE BASE CRYSTALS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-12-24 | — | — | WO | disclosed |
| US-20140005155-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC (US) | 2014-01-02 | — | — | US | disclosed |
| US-8536159-B2 | Organic compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2013-09-17 | — | — | US | disclosed |
| US-20110245214-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. | 2011-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12435093-B2 | Free base crystals | NT5C3B, NT5C, MTAP | PDE4A 741/4885PDE1A 3778/4885PDE1B 3968/4885 |
| US-20160145261-A1 | FREE BASE CRYSTALS | NT5C3B, MTAP, NT5C | PDE4A 579/4885PDE1A 3464/4885PDE1B 3676/4885 |
| US-20150038474-A1 | ORGANIC COMPOUNDS | TPMT, SULT1E1, UGT2B7 | PDE4A 2122/4885PDE1A 4789/4885PDE1B 4794/4885 |
| US-20150259353-A1 | SALT CRYSTALS | REN, SLC28A1, SLC20A1 | PDE4A 1589/4885PDE1A 2653/4885PDE1B 2536/4885 |
| US-20230174543-A1 | FREE BASE CRYSTALS | NT5C3B, MTAP, NT5C | PDE4A 656/4885PDE1A 3794/4885PDE1B 4007/4885 |
| US-20160083390-A1 | ORGANIC COMPOUNDS | TPMT, SULT1E1, UGT2B7 | PDE4A 2122/4885PDE1A 4789/4885PDE1B 4794/4885 |
| US-20140005155-A1 | ORGANIC COMPOUNDS | TPMT, SULT1E1, UGT2B7 | PDE4A 2122/4885PDE1A 4789/4885PDE1B 4794/4885 |
| US-20110245214-A1 | ORGANIC COMPOUNDS | CYP3A7, TPMT, UGT2B7 | PDE4A 2270/4885PDE1A 4752/4885PDE1B 4738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.